Call for Abstracts

The RSNA 3D Printing Special Interest Group (SIG) is accepting abstracts for the RSNA Medical 3D Printing in Practice course. This course will convene physicians and professionals working in the advanced imaging and medical 3D printing industry. It will feature didactic lectures, posters and expert demonstrations focusing on 3D printing technology, research and policy regulation in addition to a vendor exhibition area.

Types of submissions to be considered:

<table>
<thead>
<tr>
<th>Educational</th>
<th>Scientific</th>
</tr>
</thead>
<tbody>
<tr>
<td>Submission Guidelines:</td>
<td>Submission Guidelines:</td>
</tr>
<tr>
<td>• Title</td>
<td>• Title</td>
</tr>
<tr>
<td>• Author(s) and institution information</td>
<td>• Author(s) and institution information</td>
</tr>
<tr>
<td>• Teaching Points (up to 5)</td>
<td>• Teaching Points (up to 5)</td>
</tr>
<tr>
<td>• Abstract (300 words maximum):</td>
<td>• Abstract (300 words maximum):</td>
</tr>
<tr>
<td>o Introduction/Rationale</td>
<td>o Introduction/Rationale</td>
</tr>
<tr>
<td>o Results</td>
<td>o Materials and Methods</td>
</tr>
<tr>
<td>o Discussion and Conclusion</td>
<td>o Results</td>
</tr>
<tr>
<td>• One figure, graphic or chart (optional)</td>
<td>o Discussion and Conclusion</td>
</tr>
<tr>
<td></td>
<td>o References (optional)</td>
</tr>
<tr>
<td></td>
<td>• One figure, graphic or chart (optional)</td>
</tr>
</tbody>
</table>

Submitters can select their preferred method of presenting materials either orally or through poster presentation. If accepted, the Review Committee reserves the right to make final decisions on presentation method.

Timeline:

- Call for Abstracts: September 1, 2023
- Abstract Submission Deadline: October 31, 2023 at noon Central Time (CT)
- Notifications of acceptance: December 17, 2023

Policies

- Submission of an application constitutes a commitment by the author(s) to present if accepted. Failure to present and register for the course, if not justified, will jeopardize future acceptance of applications.
- Because this is an educational course, abstracts and presentations must be free of promotion/commercialization of products, must be HIPAA compliant and must consist of original work with no previously copyrighted materials, including images and media content.
- Presenters are required to register for the course. RSNA will not provide reimbursement for registration, travel or lodging for presenters.

APPLY NOW
RSNA CME Activity Disclosure Policy

Financial Relationships Disclosure and Mitigation

Per ACCME guidelines, RSNA requires that the content of its accredited CME activities provide balance, independence, objectivity, and scientific rigor. Planning and development of the clinical content and format must be free of the influence or control of a commercial entity and must promote improvements or quality in healthcare and not a specific business interest of any commercial interest (e.g., no commercial bias).

RSNA is responsible for identifying relevant financial relationships between individuals in control of educational content and ineligible companies and managing these to ensure they do not introduce commercial bias into education. Financial relationships of any dollar amount are defined as relevant if the educational content is related to the business lines or products of the ineligible company.

An ineligible company can be defined by ACCME as those whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Examples of such organizations include:

- Advertising, marketing, or communication firms whose clients are ineligible companies
- Bio-medical startups that have begun a governmental regulatory approval process
- Compounding pharmacies that manufacture proprietary compounds
- Device manufacturers or distributors
- Diagnostic labs that sell proprietary products
- Growers, distributors, manufacturers or sellers of medical foods and dietary supplements
- Manufacturers of health-related wearable products
- Pharmaceutical companies or distributors
- Pharmacy benefit managers
- Reagent manufacturers or sellers

Disclosure of Financial Relationships

If you have or have had within the previous 24 months such a relationship or affiliation, you must disclose this information. Likewise, disclosure that no relationship(s) exists is also required. The intent of this policy is not to prevent an individual with a financial relationship from participating; however, in accordance with ACCME standards, the RSNA has developed policies and procedures to manage identified financial relationships.

Sample relationships or affiliations to be disclosed follow (please note that mutual fund holdings need not be disclosed):

- Research Consultant, Peterson Pharmaceuticals
- Stockholder, Peterson Pharmaceuticals
- Speakers Bureau, Peterson Pharmaceuticals
- Research grant, Peterson Pharmaceuticals

All financial relationships must be disclosed, RSNA will determine the relevance of those relationships. You will be asked to provide the following:

a. The name of the ineligible company with which the person has a financial relationship.

b. The nature of the financial relationship. Examples of financial relationships include employee, researcher, consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and ownership interest. Individual stocks and stock options should be disclosed; diversified mutual funds do not need to be disclosed. Research funding from ineligible companies should be disclosed by the principal or named investigator even if that individual’s institution receives the research grant and manages the funds.

c. If the relationship is active or if it has ended. If ended, a date of when the relationship terminated will need to be provided.
Owners or employees of ineligible companies
Individuals that are owners or employees of ineligible companies may not control content or participate as planners or faculty in accredited education unless the content being planned or presented is not related to the business lines or products of the company.

Please note that stockholders of private ineligible companies are considered owners. As a speaker, if you are an owner or employee of an ineligible company and your topic is related to the business lines of any of the companies that you hold ownership/employment with, RSNA cannot provide CME credit for your presentation. Your topic will still be considered for presentation, just not with CME credit awarded.

Financial Relationship Mitigation
All financial relationships must be mitigated by RSNA. A staff member from RSNA will discuss any necessary steps needed to mitigate your financial relationship so that your presentation can be awarded CME credit.

Disclosure of Relationships to learners
RSNA must disclose all financial relationships (or lack thereof) for all planners and speakers to the learners before the activity.

Disclosure Refusal Statement
The requirement for financial disclosure from committee members, planners, reviewers, authors, and presenters is a mandatory element in maintaining ACCME accreditation for all organizations that provide continuing education (CE) activities. If an individual refuses to disclose, he/she will not be permitted to participate as a planner, committee member, reviewer, author, or presenter.

All RSNA accredited CME activities must be compliant with the ACCME content validation statements:

• All recommendations for patient care in accredited continuing education must be based on current science, evidence, and clinical reasoning, while giving a fair and balanced view of diagnostic and therapeutic options.

• All scientific research referred to, reported, or used in accredited education in support or justification of a patient care recommendation must conform to the accepted standards of experimental design, data collection, analysis, and interpretation.

• Although accredited continuing education is an appropriate place to discuss, debate, and explore new and evolving topics, these areas need to be clearly identified as such within the program and individual presentations. It is the responsibility of accredited providers to facilitate engagement with these topics without advocating for, or promoting, practices that are not, or not yet adequately based on current science, evidence, and clinical reasoning.

• Presentations must give a balanced view of therapeutic options by using generic names rather than trade names to maintain impartiality (e.g., use trade names from several companies, not just a single company) Educational materials that are part of a CME activity such as slides, abstracts, and handouts cannot contain any advertising, trade names without generic names, or product-group advertising.